Steven Nichtberger, M.D.

Steven Nichtberger, M.D.

President and Chief Executive OfficeratCabaletta Bio· In proxies 2022–2025

Pay in FY2024+68% from the year before · Cabaletta Bio stock -90.0% the same year

Steven Nichtberger, M.D. was paid $8.1M in FY2024 (Dec), up 68%. Cabaletta Bio stock fell 90.0% that year.

Pay$100 in the stock at the end of FY21 → $60
Pay is from the Summary Compensation Table of each Cabaletta Bio proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Cabaletta BioPublic company · 4 yr
    • President and Chief Executive Officer2022 – Present · 4 yrStock in role -63%
  2. BioAdvance Greenhouse FundPublic company
    • Director? – PresentNo stock prices for these years
  3. Alliance for Regenerative MedicinePublic company
    • Director? – PresentNo stock prices for these years
  4. Biotechnology Industry OrganizationPublic company
    • Director? – PresentNo stock prices for these years
  5. Pennsylvania BioPublic company
    • Director? – PresentNo stock prices for these years

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?